Physiologically Based Pharmacokinetic Modelling of Cabozantinib to Simulate Enterohepatic Recirculation, Drug–Drug Interaction with Rifampin and Liver Impairment

Cabozantinib (CAB) is a receptor tyrosine kinase inhibitor approved for the treatment of several cancer types. Enterohepatic recirculation (EHC) of the substance is assumed but has not been further investigated yet. CAB is mainly metabolized via CYP3A4 and is susceptible for drug–drug interactions (...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Bettina Gerner, Oliver Scherf-Clavel
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2021-05-01
coleção:	Pharmaceutics
Assuntos:	physiologically based pharmacokinetic (PBPK) modeling Cabozantinib enterohepatic recirculation drug–drug interactions (DDIs) liver impairment cytochrome P450 3A4 (CYP3A4)
Acesso em linha:	https://www.mdpi.com/1999-4923/13/6/778
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!